Palvella Therapeutics (NASDAQ:PVLA) Raised to Strong-Buy at Jones Trading

Jones Trading upgraded shares of Palvella Therapeutics (NASDAQ:PVLA) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Several other brokerages have also commented on PVLA. Canaccord Genuity Group restated a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating for the company. Scotiabank began coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Finally, TD Cowen started coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $43.20.

Palvella Therapeutics Trading Down 2.2 %

Shares of PVLA stock opened at $27.27 on Monday. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27. The company has a market cap of $306.00 million, a price-to-earnings ratio of -2.25 and a beta of 0.54. The stock has a 50 day simple moving average of $19.36.

Institutional Trading of Palvella Therapeutics

A number of hedge funds have recently made changes to their positions in PVLA. BML Capital Management LLC purchased a new position in Palvella Therapeutics during the fourth quarter valued at $506,000. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the fourth quarter valued at $171,000. ADAR1 Capital Management LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $1,736,000. Renaissance Technologies LLC bought a new position in Palvella Therapeutics in the 4th quarter worth about $256,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in Palvella Therapeutics during the 4th quarter valued at about $3,001,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.